RIGL biotech catalysts & pipeline

RIGEL PHARMACEUTICALS INC · Data as of 2026-09-08

Upcoming catalysts

R289 — Regulatory decision

H2 2026

Advanced R289 development program; Phase 1b study in patients with lower-risk MDS remains on track to complete enrollment in the dose expansion portion and select the recommended Phase 2 dose in the second half of 2026

Source filing

R289 — Topline data

Late 2026

We anticipate sharing preliminary data from the dose expansion phase of the study by the end of 2026.

Source filing

Explore the free biotech catalyst calendar